| Drug General Information |
| Drug ID |
D06WOJ
|
| Former ID |
DIB002559
|
| Drug Name |
JTH-601
|
| Synonyms |
JTH-601-G-1
|
| Indication |
Prostate disease [ICD10:N42.9]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Japan Tobacco Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
c1(c(c(c(c(c1C)O)C)C)OC)CN(CCOc1c(cc(c(c1)C)O)C(C)C)C.C<br />(=O)(/C=C/C(=O)O)O
|
| Target and Pathway |
| Target(s) |
Alpha-1D adrenergic receptor |
Target Info |
Antagonist |
[2]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Antagonist |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010685) |
|---|
| REF 2 | Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. |
|---|
